MX2019015018A - Composiciones que comprenden curones y usos de los mismos. - Google Patents
Composiciones que comprenden curones y usos de los mismos.Info
- Publication number
- MX2019015018A MX2019015018A MX2019015018A MX2019015018A MX2019015018A MX 2019015018 A MX2019015018 A MX 2019015018A MX 2019015018 A MX2019015018 A MX 2019015018A MX 2019015018 A MX2019015018 A MX 2019015018A MX 2019015018 A MX2019015018 A MX 2019015018A
- Authority
- MX
- Mexico
- Prior art keywords
- curons
- compositions
- preparations
- pharmaceutical compositions
- relates generally
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/00041—Use of virus, viral particle or viral elements as a vector
- C12N2750/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518898P | 2017-06-13 | 2017-06-13 | |
| US201762597387P | 2017-12-11 | 2017-12-11 | |
| US201862676730P | 2018-05-25 | 2018-05-25 | |
| PCT/US2018/037379 WO2018232017A1 (en) | 2017-06-13 | 2018-06-13 | Compositions comprising curons and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019015018A true MX2019015018A (es) | 2020-09-10 |
Family
ID=62846247
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015018A MX2019015018A (es) | 2017-06-13 | 2018-06-13 | Composiciones que comprenden curones y usos de los mismos. |
| MX2023011657A MX2023011657A (es) | 2017-06-13 | 2019-12-11 | Composiciones que comprenden curones y usos de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011657A MX2023011657A (es) | 2017-06-13 | 2019-12-11 | Composiciones que comprenden curones y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20200123203A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3638797A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2020524993A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20200038236A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111108208A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018285860A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019026226A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3066750A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL271275A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2019015018A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018232017A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
| US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
| WO2020123773A2 (en) * | 2018-12-12 | 2020-06-18 | Flagship Pioneering Innovations V, Inc. | Anellosomes for delivering secreted therapeutic modalities |
| KR20210131308A (ko) * | 2018-12-12 | 2021-11-02 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포내 치료 양식을 운반하기 위한 아넬로좀 |
| US20220042042A1 (en) * | 2018-12-12 | 2022-02-10 | Flagship Pioneering Innovations V, Inc. | Anellosomes and methods of use |
| BR112021010925A2 (pt) * | 2018-12-12 | 2021-08-31 | Flagship Pioneering Innovations V, Inc | Anelossomos para entrega de modalidades terapêuticas de substituição de proteína |
| CA3143327A1 (en) | 2019-06-13 | 2020-12-17 | J. Keith Joung | Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells |
| EP3999642A1 (en) | 2019-07-19 | 2022-05-25 | Flagship Pioneering Innovations VI, LLC | Recombinase compositions and methods of use |
| CN116075591A (zh) * | 2020-06-12 | 2023-05-05 | 旗舰先锋创新V股份有限公司 | 串联型指环病毒构建体 |
| EP4164667A4 (en) * | 2020-06-12 | 2024-10-23 | Flagship Pioneering Innovations V, Inc. | Baculovirus expression systems |
| JP2023530451A (ja) * | 2020-06-17 | 2023-07-18 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | アネロウイルスを同定し及び特徴付ける方法並びにその使用 |
| CN116670154A (zh) | 2020-07-24 | 2023-08-29 | 总医院公司 | 增强的病毒样颗粒及使用其递送至细胞的方法 |
| US12018254B2 (en) * | 2020-07-27 | 2024-06-25 | Wisconsin Alumni Research Foundation | Methods of making unbiased phage libraries |
| IL303892A (en) * | 2020-12-23 | 2023-08-01 | Flagship Pioneering Innovations V Inc | In vitro assembly of RNA-encapsulating enalavirus capsids |
| CN117279669A (zh) * | 2021-02-08 | 2023-12-22 | 旗舰先锋创新V股份有限公司 | 杂合aav-指环载体 |
| US20250027107A1 (en) * | 2021-10-18 | 2025-01-23 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| WO2025194138A1 (en) | 2024-03-14 | 2025-09-18 | Tessera Therapeutics, Inc. | St1cas9 compositions and methods for modulating a genome |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR751473A (fr) * | 1932-06-01 | 1933-09-04 | Poste d'incendie | |
| JP2001500015A (ja) | 1996-09-06 | 2001-01-09 | トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法 |
| US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US6395472B1 (en) * | 1999-02-05 | 2002-05-28 | Abbott Laboratories | Methods of utilizing the TT virus |
| EP2338478B1 (en) | 2002-06-28 | 2014-07-23 | Protiva Biotherapeutics Inc. | Method for producing liposomes |
| JP4951338B2 (ja) | 2003-07-16 | 2012-06-13 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質に封入された干渉ｒｎａ |
| JP4842821B2 (ja) | 2003-09-15 | 2011-12-21 | プロチバ バイオセラピューティクス インコーポレイティッド | ポリエチレングリコール修飾脂質化合物およびその使用 |
| EP2514758B2 (en) | 2004-03-15 | 2021-06-23 | City of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| AU2005252273B2 (en) | 2004-06-07 | 2011-04-28 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| CA2571899A1 (en) | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
| WO2007048046A2 (en) | 2005-10-20 | 2007-04-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of filovirus gene expression |
| EP1948674A4 (en) | 2005-11-02 | 2009-02-04 | Protiva Biotherapeutics Inc | MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF |
| US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| JP5475753B2 (ja) | 2008-04-15 | 2014-04-16 | プロチバ バイオセラピューティクス インコーポレイティッド | 核酸送達用の脂質製剤 |
| US20100184841A1 (en) | 2008-12-18 | 2010-07-22 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| US8603966B2 (en) | 2009-02-27 | 2013-12-10 | The Administrators Of The Tulane Educational Fund | Amino acid-based compounds, their methods of use, and methods of screening |
| CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| EP2449106B1 (en) | 2009-07-01 | 2015-04-08 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing apolipoprotein b |
| US9676828B2 (en) * | 2010-06-23 | 2017-06-13 | Deutsches Krebsforschungszentrum | Rearranged TT virus molecules for use in diagnosis, prevention and treatment of cancer and autoimmunity |
| SG194099A1 (en) * | 2011-04-15 | 2013-11-29 | Compugen Ltd | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
| GB2537000C (en) | 2012-05-25 | 2019-10-09 | Univ California | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| EP4556564A3 (en) | 2012-10-23 | 2025-09-03 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| PL2771468T3 (pl) | 2012-12-12 | 2015-07-31 | Broad Inst Inc | Inżynieria systemów, metod i zoptymalizowanych kompozycji kierujących dla manipulacji sekwencjami |
| US20140186919A1 (en) | 2012-12-12 | 2014-07-03 | Feng Zhang | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| KR20150105635A (ko) | 2012-12-12 | 2015-09-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2015089419A2 (en) * | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
-
2018
- 2018-06-13 JP JP2019568601A patent/JP2020524993A/ja not_active Withdrawn
- 2018-06-13 KR KR1020207000972A patent/KR20200038236A/ko not_active Ceased
- 2018-06-13 MX MX2019015018A patent/MX2019015018A/es unknown
- 2018-06-13 KR KR1020257004957A patent/KR20250028508A/ko active Pending
- 2018-06-13 EP EP18738411.0A patent/EP3638797A1/en active Pending
- 2018-06-13 CA CA3066750A patent/CA3066750A1/en active Pending
- 2018-06-13 BR BR112019026226-1A patent/BR112019026226A2/pt unknown
- 2018-06-13 WO PCT/US2018/037379 patent/WO2018232017A1/en not_active Ceased
- 2018-06-13 AU AU2018285860A patent/AU2018285860A1/en not_active Abandoned
- 2018-06-13 US US16/622,146 patent/US20200123203A1/en not_active Abandoned
- 2018-06-13 CN CN201880051296.6A patent/CN111108208A/zh active Pending
-
2019
- 2019-03-27 US US16/366,571 patent/US20190211361A1/en not_active Abandoned
- 2019-12-09 IL IL271275A patent/IL271275A/en unknown
- 2019-12-11 MX MX2023011657A patent/MX2023011657A/es unknown
-
2020
- 2020-01-16 US US16/744,363 patent/US20200385757A1/en not_active Abandoned
-
2022
- 2022-07-15 US US17/812,896 patent/US20230279423A1/en not_active Abandoned
- 2022-11-24 JP JP2022187239A patent/JP2023010961A/ja not_active Withdrawn
-
2024
- 2024-04-23 JP JP2024069618A patent/JP2024087003A/ja active Pending
-
2025
- 2025-01-24 AU AU2025200497A patent/AU2025200497A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190211361A1 (en) | 2019-07-11 |
| US20230279423A1 (en) | 2023-09-07 |
| MX2023011657A (es) | 2023-10-11 |
| BR112019026226A2 (pt) | 2020-06-30 |
| EP3638797A1 (en) | 2020-04-22 |
| RU2020100074A3 (cg-RX-API-DMAC7.html) | 2022-02-08 |
| AU2025200497A1 (en) | 2025-04-10 |
| JP2020524993A (ja) | 2020-08-27 |
| JP2024087003A (ja) | 2024-06-28 |
| IL271275A (en) | 2020-01-30 |
| RU2020100074A (ru) | 2021-08-03 |
| JP2023010961A (ja) | 2023-01-20 |
| CN111108208A (zh) | 2020-05-05 |
| WO2018232017A1 (en) | 2018-12-20 |
| KR20250028508A (ko) | 2025-02-28 |
| KR20200038236A (ko) | 2020-04-10 |
| AU2018285860A1 (en) | 2020-01-02 |
| CA3066750A1 (en) | 2018-12-20 |
| US20200123203A1 (en) | 2020-04-23 |
| US20200385757A1 (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023011657A (es) | Composiciones que comprenden curones y usos de los mismos. | |
| WO2020198403A3 (en) | Compositions comprising modified circular polyribonucleotides and uses thereof | |
| MX2021014956A (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos. | |
| MX2023010042A (es) | Polinucleotidos moduladores. | |
| MX2019001313A (es) | Composiciones farmaceuticas. | |
| EP4620519A3 (en) | Methods and compositions relating to chondrisomes from blood products | |
| MX2021006977A (es) | Anellosomas y metodos de uso. | |
| EP4279071A3 (en) | Novel cannabinoid formulations | |
| PH12016501441A1 (en) | Chimeric alkaline phosphate-like proteins | |
| PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2019010984A (es) | Composiciones de sintecina y metodos de uso. | |
| MX2019005855A (es) | Formulaciones que se pueden pulverizar. | |
| MX2019002057A (es) | Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc. | |
| CL2019001053A1 (es) | Formulaciones farmacéuticas y métodos para prepararlas. | |
| MX2021006941A (es) | Anelosomas para suministrar modalidades terapéuticas intracelulares. | |
| PH12017502028A1 (en) | Vortioxetine pyroglutamate | |
| PH12020551618A1 (en) | Erenumab compositions and uses thereof | |
| IL272834A (en) | Compositions of amantadine, their preparation, and methods of use | |
| IN2014CH00840A (cg-RX-API-DMAC7.html) | ||
| PH12017502277A1 (en) | Multi-specific binding proteins | |
| MX2020013389A (es) | Composiciones de terlipresina y usos de las mismas. | |
| PH12020550795A1 (en) | Methods of using and compositions containing dulaglutide | |
| EP4582145A3 (en) | Solid state forms of ixazomib citrate | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations |